Rabin Medical Center

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Citigroup, Rabin Medical Center, Biomedicine, Biomedical engineering, Partnership, Tiger Management, Business, Duke University, Duke University Hospital, NDA, Acquisition, Credit Suisse, University, MD Anderson Cancer Center, Therapy, Bangladesh Technical Education Board, STAT3, Pharmaceutical industry

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.

Key Points: 
  • Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D.
  • Formerly, Mr. Shah was a healthcare investment banker for global investment banks Citigroup and Credit Suisse.
  • Newly appointed board member Dr. Wirk has more than 20 years of investment experience in public and private life science companies.
  • “The appointment of Sujal as Chairman and the addition of Shaheen to Tvardi’s Board of Directors are instrumental to the success of Tvardi,” said Imran Alibhai, Ph.D., CEO of Tvardi.

Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases

Retrieved on: 
Thursday, February 29, 2024
Clalit Health Services, Medical imaging, ARC, 3D, Radiology, X-ray, Lung, Radiation, LTD, Risk, Beilinson, Rabin Medical Center, Patient, Trial of the century, CAC, Partnership

PETAH TIKVA, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and Beilinson Hospital, a leading Israeli hospital and part of Rabin Medical Center, owned and operated by Israel’s largest healthcare organization, Clalit Health Services, today announced their collaboration to conduct a clinical study evaluating the Nanox.ARC 3D imaging system in a clinical outpatient setting at Beilinson Hospital. The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults. Such a study may help determine the clinical utility of the additional information provided by the 3D tomographic imaging, potentially preventing the need for more advanced imaging and exposure to additional radiation.

Key Points: 
  • The study will specifically assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults.
  • The study is being led by Professor Eli Atar, M.D., FSIR, Director of the Department of Imaging, and Dr. Ahuva Grubstein, M.D., Department of Diagnostic Radiology, both at Beilinson Hospital.
  • This study evaluating the Nanox.ARC is an addition to the existing collaboration between Nanox AI and Clalit, and the second study conducted with Beilinson Hospital.
  • “This technology shows promise to expand clinicians’ capabilities for more precise readings and earlier detection across a range of pulmonary conditions.

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

Retrieved on: 
Tuesday, February 20, 2024
PHD, Incidence, HMO, Principal, Inflammation, Pressure, Calibration, Infrared, Skin, Methodism, Standard of care, Conference, Safety, Nursing, Biomarker, Rabin Medical Center, Patient, Clalit Health Services, CSO, Diagnosis, Trial of the century, Medical device

The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.

Key Points: 
  • The objective of the study was to evaluate the sensitivity, specificity, and usability of PressureSafe to detect early-stage pressure injuries Stage 1 / suspected deep tissue injuries (sDTI) before skin breakage, compared to standard of care.
  • PressureSafe detected biomarkers and changes in tissue structures under the skin’s surface as they relate to pressure injuries.
  • The 14-day efficacy portion of the single arm, bi-center study evaluated 38 patients at high risk of pressure injury development.
  • Based on these data, the study concluded that PressureSafe is a safe, efficient, and valuable method for early detection of pressure injuries.

IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16

Retrieved on: 
Tuesday, February 13, 2024
Hospital, HMO, Health, Infrared, Trial of the century, Principal investigator, Death, Conference, Safety, Rabin Medical Center, Patient, Clalit Health Services, Medical device

The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.

Key Points: 
  • The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe ™ , IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection.
  • IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries.
  • Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.
  • PressureSafe was found to be over 90% accurate in detecting pressure injuries based on interim results from a multicenter study.

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

Retrieved on: 
Monday, December 4, 2023
Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Symantec Endpoint Protection, Dor, NYSE, Safety, CANF, Rabin Medical Center, Treatment, RECIST, Duration, Disease, Liver cancer, RAS, Patient, Inflammation, Growth, PFS, Pharmacokinetics, DCR, Activity, Conference, ORR, Trial of the century, Survival, Phase, Cancer, Rated R, Progression-free survival, TASE, AACR, Pharmaceutical industry

Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.

Key Points: 
  • Can-Fite completed the protocol design of the CF102-222PC clinical study entitled: “A Phase II Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma”.
  • This is a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least 1st-line therapy or who refuse standard treatment.
  • The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population.
  • “This Phase IIa study is designed as an open-label one, enabling us to assess the safety and potential efficacy of Namodenoson in pancreatic cancer patients whose disease has progressed despite first-line treatment.

In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

Retrieved on: 
Monday, December 11, 2023
Food and Drug Administration, Inspira Health Network, Food, Rabin Medical Center, Risk, Patient, Extracorporeal membrane oxygenation, OXY, FDA, Annual report, Nursing care plan, Cardiothoracic surgery, Unitary state, Pharmaceutical industry, Medical device

Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.
  • Dr. Gorfil's expertise are expected to significantly contribute to the deployment of the INSPIRA™ ART100.
  • "My commitment to life support innovation led me to Inspira Technologies," stated Dr. Gorfil.
  • Dagi Ben-Noon, CEO of Inspira Technologies, commented, "Dr. Gorfil's appointment represents a strategic step towards accelerating our technology's time-to-market.

Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

Retrieved on: 
Thursday, September 28, 2023
Clalit Health Services, Insurance, CE, Fatty liver disease, CT, Radiation, European Heart Journal: Cardiovascular Imaging, Osteoporosis, Rabin Medical Center, Cardiovascular disease, HMO, CT scan, Trial of the century, Radiology, CAC, Patient, Physician, Non-alcoholic fatty liver disease, Mortality, FDA, LTD, Artifact, Disease, Medical device, Medical imaging

NEVE ILAN, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that HealthCCSng, an AI-powered solution created by Nanox’s deep-learning medical imaging analytics subsidiary, Nanox.AI, was used in a clinical study evaluating routine CT scans and found that 58% of patients unknowingly had moderate to severe levels of coronary artery calcium (CAC), a proven indicator of future cardiac events. The study was sponsored by Nanox.AI and conducted by the Beilinson Hospital, one of the largest and most renowned multidisciplinary medical institutions in Israel, and utilized Nanox.AI’s HealthCCSng, an FDA-cleared and CE marked tool designed specifically for cardiac health assessment.

Key Points: 
  • Nanox.AI’s HealthCCSng solution utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC category.
  • CAC is the strongest predictor of future cardiac events, with patients in the highest category being over 20 times more likely to suffer a cardiac event.
  • “The patients in this study received routine CT scans that had nothing to do with a cardiac concern.
  • HealthCCSng supports clinicians in diagnosing patients with cardiovascular disease who were previously undetected, while stratifying such patients so that they can obtain the appropriate preventative cardiac care and treatment.

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Retrieved on: 
Tuesday, August 15, 2023
Rambam Health Care Campus, Therapy, ICI, RMC, RCC, Rabin Medical Center, Bristol Myers Squibb, Coronavirus Scientific Advisory Board, Hope, Research, NSCLC, Lung cancer, Immunotherapy, Patient, Melanoma, TASE, Treatment, Safety, Renal cell carcinoma, Pharmaceutical industry

The Davidoff Center for the Treatment and Research of Cancer, situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a preeminent position as Israel's first and foremost comprehensive cancer center, known for its international leadership in cancer care.

Key Points: 
  • The Davidoff Center for the Treatment and Research of Cancer, situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a preeminent position as Israel's first and foremost comprehensive cancer center, known for its international leadership in cancer care.
  • This new site at The Davidoff Center represents another milestone in Biomica's commitment to advancing cutting-edge clinical research in immuno-oncology.
  • Prof. Gal Markel, Director of Davidoff Cancer Center and Biomica's Scientific Advisory Board member, said: "I am excited about Biomica's significant progress in their Phase I clinical trial at The Davidoff Cancer Center.
  • Dr. Elran Haber, CEO of Biomica, expressed his pride: "The opening of this new site at The Davidoff Center, a world-renowned cancer institution, marks an important milestone for Biomica's BMC128 clinical program.

IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care

Retrieved on: 
Monday, July 17, 2023
Clalit Health Services, Pressure, Interim, Health, Bed, Eye, HMO, Rabin Medical Center, Biomarker, Trial of the century, Wheelchair, U.S. FDA, Ischemia, Patient, FDA, Skin, Safety, Medical imaging, Petah Tikva

PressureSafe demonstrated very high efficacy in noninvasively detecting the presence and absence of pressure injuries below the skin’s surface.

Key Points: 
  • PressureSafe demonstrated very high efficacy in noninvasively detecting the presence and absence of pressure injuries below the skin’s surface.
  • Pressure injuries can occur when a patient must stay in a wheelchair or bed and isn’t able to move.
  • Currently, visual inspection is used to detect and classify pressure injuries according to depth, width, degree of tissue loss, and presence of granulated tissue.
  • $26.8 billion is spent each year to prevent and treat pressure injuries that result from long-term pressure on hard surfaces such as wheelchairs and beds.

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Retrieved on: 
Tuesday, June 13, 2023
Finance, FDA, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Acumen, Survival rate, Pancreatic cancer, Male, Therapy, Hepatocellular carcinoma, Hepatology, Progression-free survival, European Medicines Agency, American Society of Clinical Oncology, Clinical trial, Rabin Medical Center, Cancer, EMA, ASCO, Incidence, Patient, CANF, Kidwai Memorial Institute of Oncology, TASE, Safety, IND, Society, NYSE, Female, Disease, Pharmaceutical industry

Pre-clinical studies demonstrate a robust dose dependent anti-proliferative effect of Namodenoson on pancreatic carcinoma cells originating from both male and female patients, reaching 90% growth inhibition.

Key Points: 
  • Pre-clinical studies demonstrate a robust dose dependent anti-proliferative effect of Namodenoson on pancreatic carcinoma cells originating from both male and female patients, reaching 90% growth inhibition.
  • An open-label Phase 2 exploratory trial to assess the safety and efficacy of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy will be initiated.
  • The IND submission will cross reference all the data previously shared with the FDA related to the development of Namodenoson for the treatment of advanced liver cancer.
  • Acumen Research estimates the global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow to approximately $6.6 billion by 2030.